natgillin/translations-raw huggingface dataset:
4 Acute coronary syndrome As with other nicotinic acid medicinal products, caution should be used when Pelzont is used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive medicinal products such as nitrates, calcium channel blockers, or adrenergic blocking agents.
Sindrom coronarian acut Similar altor medicamente care conţin acid nicotinic, este necesară precauţie atunci când Pelzont este utilizat la pacienţi cu angină instabilă sau în faza acută a unui infarct miocardic (IM), mai ales când astfel de pacienţi utilizează, de asemenea, medicamente vasoactive cum sunt nitraţi, blocante ale canalelor de calciu sau blocante adrenergice.
Haematologic effects As with other nicotinic acid medicinal products, Pelzont (2000 mg/ 40 mg) was associated with small reductions in platelet count (see section 4.8).
4. 8).
Effect on uric acid As with other nicotinic acid medicinal products, Pelzont (2000 mg/ 40 mg) was associated with small increases in uric acid levels (see section 4.8).
4. 8).
Hypophosphatemia As with other nicotinic acid medicinal products, Pelzont was associated with small decreases in phosphorus levels.
Hipofosfatemie Similar altor medicamente care conţin acid nicotinic, Pelzont a fost asociat cu reduceri mici ale valorilor fosforului.
Further As with other nicotinic acid medicinal products, patients with a history of jaundice, hepato-biliary disorder or peptic ulcer should be observed closely (see sections 4.2 and 4.3).
4. 2 şi 4. 3).
Excipient Pelzont contains lactose.
Excipient Pelzont conţine lactoză.
Simultaneous use of alcohol or hot drinks can enhance the effects of flushing and should therefore be avoided around the time of ingestion of Pelzont.
Utilizarea simultană de alcool etilic sau băuturi fierbinţi poate accentua efectele de hiperemie cutanată tranzitorie şi de aceea trebuie evitată în apropierea momentului administrării Pelzont.
Nicotinic acid Effects of nicotinic acid on other medicinal products Antihypertensive therapy:
Acid nicotinic Efectele acidului nicotinic asupra altor medicamente Tratament antihipertensiv:
Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive medicinal products such as nitrates, calcium channel blockers, and adrenergic receptor blocking agents, resulting in postural hypotension.
Acidul nicotinic poate potenţa efectele ganglioplegicelor şi ale medicamentelor vasoactive cum sunt nitraţi, blocante ale canalelor de calciu şi blocante de receptori adrenergici, ducând la apariţia hipotensiunii ortostatice.
When simvastatin is combined with nicotinic acid, a modest increase in AUC and Cmax of simvastatin acid (the active form of simvastatin) was observed, which may be devoid of clinical relevance.
Când simvastatina este asociată cu acidul nicotinic, se observă o creştere modestă a ASC şi Cmax de simvastatină acidă (forma activă a simvastatinei), care poate să nu prezinte nicio importanţă clinică.
The pharmacokinetic interaction of Pelzont with statins has been studied only with simvastatin (see section 4.4).
4. 4).
Effects of other medicinal products on nicotinic acid Bile acid sequestrants:
Efectele altor medicamente asupra acidului nicotinic Chelatori de acizi biliari:
Because co-administration of bile acid sequestrants may reduce the bioavailability of acidic medicinal products such as nicotinic acid, it is recommended that Pelzont be administered > 1 hour before or > 4 hours after administration of a bile acid sequestrant.
Deoarece administrarea concomitentă a chelatorilor de acizi biliari poate reduce biodisponibilitatea medicamentelor acide cum este acidul nicotinic, se recomandă ca Pelzont să fie administrat cu > 1 oră înainte sau la > 4 ore după administrarea unui chelator de acizi biliari.
5 Supplements containing nicotinic acid:
Suplimente conţinând acid nicotinic:
Vitamins or other nutritional supplements containing (≥ 50 mg/ day) of nicotinic acid (or nicotinamide) have not been studied with Pelzont.
Vitaminele sau alte suplimente nutriţionale care conţin acid nicotinic (sau nicotinamidă) (≥ 50 mg/ zi) nu au fost studiate în asociere cu Pelzont.
Medicinal product / laboratory test interactions:
Interacţiuni medicament/ analize de laborator:
In urine glucose tests, nicotinic acid may also give false-positive reactions with cupric sulfate solution (Benedict’ s reagent).
În cazul testării glucozei în urină, acidul nicotinic poate, de asemenea, să determine apariţia reacţiilor fals pozitive cu soluţia de sulfat de cupru (reactivul Benedict).
Laropiprant Effects of laropiprant on other medicinal products Midazolam:
Laropiprant Efectele laropiprantului asupra altor medicamente Midazolam:
Multiple doses of laropiprant 40 mg did not affect the pharmacokinetics of midazolam, a sensitive CYP3A4 substrate.
Dozele multiple de laropiprant 40 mg nu au influenţat parametrii farmacocinetici ai midazolamului, un substrat sensibil al CYP3A4.
However, the plasma concentration of a metabolite of midazolam, 1'-hydroxymidazolam, was increased approximately 2-fold with multiple doses of laropiprant.
Cu toate acestea, concentraţia plasmatică a unui metabolit al midazolamului, 1 '- hidroximidazolam, a fost crescută de aproximativ 2 ori în cazul dozelor multiple de laropiprant.
Because 1'-hydroxymidazolam is an active metabolite, the sedative effect of midazolam may be increased and caution should be used when laropiprant is co-administered with midazolam.
Deoarece 1 '- hydroxymidazolamul este un metabolit activ, efectul sedativ al midazolamului poate fi crescut şi este necesară precauţie în cazul administrării concomitente a laropiprantului cu midazolam.
Other medicinal products:
5 Alte medicamente:
Co-administration of laropiprant 40 mg with midazolam increased the AUC0-∞ and Cmax of 1'-hydroxymidazolam, a midazolam metabolite, by 98% and 59%, respectively.
Administrarea concomitentă de laropiprant 40 mg cu midazolam a determinat creşterea ASC0- ∞ şi Cmax de 1 ’ - hidroximidazolam, un metabolit al midazolamului, cu 98% şi, respectiv, 59%.
1'-hydroxymidazolam is metabolised predominantly by uridine diphosphate-glucuronosyltransferases (UGT) 2B4 and 2B7.
1 ’ - hidroximidazolamul este metabolizat predominant de către uridin difosfat glucuroniltransferazele (UGT) 2B4 şi 2B7.
Clinical and in vitro studies support the conclusion that laropiprant is a mild to moderate inhibitor of UGT2B4/ UGT2B7.
Studiile clinice şi in vitro susţin concluzia că laropiprantul este un inhibitor uşor spre moderat al UGT2B4/ UGT2B7.
Based on these data, laropiprant is not expected to cause interactions with substrates of CYP isozymes 3A4, 2C9, 2C8 and human P-glycoprotein (P-gp).
Pe baza acestor date, nu este de aşteptat ca laropiprantul să prezinte interacţiuni cu substraturi ale izoenzimelor CYP 3A4, 2C9, 2C8 şi cu glicoproteina P umană (P- gp).
In a clinical study, there was no meaningful effect of laropiprant on the inhibition of ADP-induced platelet aggregation by clopidogrel, but there was a modest increase in the inhibition of collagen-induced platelet aggregation by clopidogrel.
Într- un studiu clinic, nu a existat niciun efect semnificativ al laropiprantul asupra inhibării de către clopidogrel a agregării plachetare induse de ADP, dar a existat o creştere modestă a inhibării de către clopidogrel a agregării plachetare induse de colagen.
The clinical significance of these observations is unknown.
Nu se cunoaşte semnificaţia clinică a acestor observaţii.
In a clinical study, concomitant administration of laropiprant with acetylsalicylic acid did not have an effect on collagen-induced platelet aggregation or on bleeding time compared to treatment with acetylsalicylic acid alone (see section 5.1).
5. 1).
Effects of other medicinal products on laropiprant CYP3A4 Inhibitor:
Efectele altor medicamente asupra laropiprantului Inhibitori ai CYP3A4:
Clarithromycin (a potent inhibitor of CYP3A4 and P-gp) did not have a clinically meaningful effect on the pharmacokinetics of laropiprant.
Claritromicina (un inhibitor puternic al CYP3A4 şi P- gp) nu a avut un efect clinic semnificativ asupra parametrilor farmacocinetici ai laropiprantului.
Laropiprant is not a substrate of human P-gp, and therefore other inhibitors of CYP3A4 and/ or P-gp are also not expected to have a clinically meaningful impact on the pharmacokinetics of laropiprant.
Laropiprantului nu este un substrat pentru P- gp umană şi, de aceea, nu este de aşteptat ca alţi inhibitori de CYP3A4 şi/ sau P- gp să aibă o influenţă semnificativă din punct de vedere clinic asupra parametrilor farmacocinetici ai laropiprantului.
Pregnancy Pelzont There are no data from the combined use of nicotinic acid and laropiprant in pregnant women.
Pelzont Nu există date privind utilizarea combinată a acidului nicotinic şi laropiprantului la femeile gravide.
Nicotinic acid There are no adequate data from the use of high dose nicotinic acid in pregnant women.
Acid nicotinic Nu există date adecvate privind utilizarea dozelor mari de acid nicotinic la femeile gravide.
Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).
5. 3).
Laropiprant There are no data from the use of laropiprant in pregnant women.
Laropiprant Nu există date privind utilizarea laropiprantului la femeile gravide.
Studies in animals have shown reproductive toxicity at high doses of laropiprant (see section 5.3).
5. 3).
Lactation Pelzont No studies in lactating animals have been conducted with Pelzont.
Pelzont Nu s- au efectuat studii cu Pelzont la animalele aflate în perioada de alăptare.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Pelzont to the woman.
Decizia de a continua/ întrerupe alăptarea sau de a continua/ întrerupe tratamentul trebuie să fie luată ţinând cont de beneficiul alăptării pentru copil şi de beneficiul Pelzont pentru mamă.
Nicotinic acid Nicotinic acid is excreted in human breast milk.
6 Acid nicotinic Acidul nicotinic este excretat în laptele uman.
Laropiprant It is unknown whether laropiprant is excreted in human breast milk.
Laropiprant Nu se cunoaşte dacă laropiprantul este excretat în laptele uman.
However, when driving vehicles or operating machines, it should be taken into account that dizziness has been reported (see section 4.8).
4. 8).
4.8 Undesirable effects In clinical trials, over 2500 patients received Pelzont alone or with an HMG-CoA reductase inhibitor.
În studiile clinice, la peste 2500 pacienţi s- a administrat Pelzont în monoterapie sau împreună cu un inhibitor de HMG- CoA reductază.
Adverse reactions have usually been mild and transient.
Reacţiile adverse au fost, în general, uşoare şi tranzitorii.
Flushing Flushing is the most common adverse reaction of Pelzont.
Hiperemie cutanată tranzitorie Hiperemia cutanată tranzitorie este cea mai frecventă reacţie adversă a Pelzont.
In a pool of four active- or placebo-controlled clinical trials (N=2548), flushing was reported by the investigator as a possibly, probably, or definitely treatment-related adverse reaction in 12.3% of patients taking Pelzont.
Într- o serie de patru studii clinice controlate cu comparator activ sau cu placebo (N=2548), apariţia hiperemiei cutanate tranzitorii a fost raportată de către investigator ca fiind o reacţie adversă posibil, probabil sau în mod clar asociată tratamentului la 12, 3% dintre pacienţii cărora li s- a administrat Pelzont.
In these studies, the percentage of patients taking Pelzont, nicotinic acid (pooled prolonged-release formulations) or pooled placebo/ simvastatin who discontinued due to any flushing-related symptom (redness, warmth, itching and tingling) was 7.2%, 16.6%, and 0.4%, respectively.
În aceste studii clinice, procentul de pacienţi care a utilizat Pelzont, acid nicotinic (forme farmaceutice cu eliberare prelungită cumulate) sau placebo/ simvastatină cumulat şi care au întrerupt tratamentul din cauza oricărui simptom legat de hiperemia cutanată tranzitorie (roşeaţă, căldură, prurit şi parestezii) a fost de 7, 2%, 16, 6% şi, respectiv de 0, 4%.
Discontinuations due to other specific adverse reactions among patients taking Pelzont were infrequent (< 1%).
Întreruperile tratamentului din cauza altor reacţii adverse specifice la pacienţii cărora li s- a administrat Pelzont au fost ocazionale (< 1%).
7 Overall adverse reactions with Pelzont In addition to flushing, clinical adverse reactions reported by the investigators as possibly, probably, or definitely related to Pelzont in ≥ 1% of patients treated with Pelzont alone (n=947) or co-administered with statin (n=1601) and clinically meaningful adverse reactions (< 1%), for up to one year are listed below.
Totalitatea reacţiilor adverse asociate cu Pelzont Pe lângă hiperemia cutanată tranzitorie, reacţiile adverse clinice raportate de către investigatori ca fiind posibil, probabil sau sigur asociate administrării Pelzont, apărute la ≥ 1% dintre pacienţii trataţi cu Pelzont în monoterapie (n=947) sau la care s- a administrat concomitent o statină (n=1601) şi reacţiile adverse importante din punct de vedere clinic (< 1%), timp de până la un an sunt enumerate mai jos.
The frequencies of adverse reactions are ranked according to the following:
Frecvenţele reacţiilor adverse sunt clasificate după cum urmează:
Very common (≥ 1/ 10), Common (≥ 1/ 100 to < 1/ 10), Uncommon (≥ 1/ 1,000 to < 1/ 100), Rare (≥ 1/ 10,000 to < 1/ 1,000), Very rare (< 1/ 10,000).
Foarte frecvente (≥ 1/ 10), Frecvente (≥ 1/ 100 şi < 1/ 10), Mai puţin frecvente (≥ 1/ 1000 şi < 1/ 100), Rare (≥ 1/ 10000 şi < 1/ 1000), Foarte rare (< 1/ 10000).
System organ class Investigations
Clasificare pe aparate, sisteme şi organe
Adverse reaction elevations in ALT and/ or AST (consecutive, ≥ 3 X ULN), fasting glucose, uric acid (see below)
creşteri ale valorilor ALT şi/ sau AST (≥3 ori LSN, consecutiv), glicemiei în condiţii de repaus alimentar, acidului uric (vezi mai jos)
elevations in CK (≥ 10 X ULN), total bilirubin, reductions in phosphorus and platelet counts (see below)
creşteri ale valorilor CK (≥10 ori LSN), bilirubinei totale, scăderi ale valorilor fosforului şi ale numărului de trombocite (vezi mai jos)
Nervous system disorders Gastrointestinal disorders Skin and subcutaneous tissue disorders
Tulburări ale sistemului nervos Tulburări gastro- intestinale Afecţiuni cutanate şi ale ţesutului subcutanat
dizziness, headache, paraesthesia diarrhoea, dyspepsia, nausea, vomiting erythema, pruritus, rash, urticaria
ameţeli, cefalee, parestezii diaree, dispepsie, greaţă, vărsături eritem, prurit, erupţii cutanate tranzitorii, urticarie
flushing
hiperemie cutanată tranzitorie
feeling hot
senzaţie de căldură
Hypersensitivity reaction (see below)
Reacţii de hipersensibilitate (vezi mai jos)
An apparent hypersensitivity reaction has been reported (< 1%) This is characterised by multiple symptoms that may include: angio-oedema, pruritus, erythema, paraesthesia, loss of consciousness, vomiting, urticaria, flushing, dyspnoea, nausea, incontinence of urine and stool, cold sweats, shivering, chills, increased blood pressure, lip swelling, burning sensation, drug eruption, arthralgia, leg swelling, and tachycardia.
Aceasta este caracterizată prin simptome multiple care pot include: edem angioneurotic, prurit, eritem, parestezii, pierderea cunoştinţei, vărsături, urticarie, hiperemie cutanată tranzitorie, dispnee, greaţă, incontinenţă urinară şi fecală, transpiraţii reci, tremor, frisoane, creşterea tensiunii arteriale, edemaţierea buzelor, senzaţie de arsură, erupţie medicamentoasă, artralgii, edem la nivelul membrelor inferioare şi tahicardie.
Investigations Marked and persistent increases of serum transaminases have been reported infrequently (see section 4.4).
Investigaţii diagnostice Au fost raportate ocazional creşteri marcate şi persistente ale valorilor transaminazelor serice (vezi pct.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/ or AST ≥ 3 X ULN, consecutive) was 1.0% for patients treated with Pelzont with or without a statin.
În studiile clinice controlate, incidenţa creşterilor cu importanţă clinică ale valorilor transaminazelor serice (ALT şi/ sau AST ≥ 3 ori LSN, consecutiv) a fost de 1, 0% pentru pacienţii trataţi cu Pelzont cu sau fără o statină.
Clinically important elevations of CK (≥ 10 X ULN) were seen in 0.3% of the patients treated with Pelzont with or without a statin (see section 4.4).
4. 4).
Other abnormal laboratory values reported were elevations in LDH, fasting glucose, uric acid, total bilirubin, and amylase, and reductions in phosphorus and platelet counts (see section 4.4).
4. 4).
As with other nicotinic acid medicinal products, elevations in fasting glucose (a median increase of approximately 4 mg/ dL), and uric acid (mean change from baseline of +14.7%), and reductions in platelet counts (a mean change from baseline of -14.0%) were reported in
4. 4).
In diabetic patients a median increase in HbA1c of 0.2% was observed (where modification of hypoglycaemic therapy was allowed).
La pacienţii diabetici a fost observată o creştere mediană a HbA1c cu 0, 2% (când a fost permisă modificarea tratamentului hipoglicemiant).
Nicotinic acid-related adverse reactions The following nicotinic acid-related adverse reactions have been seen in clinical trials or post-marketing experience with other nicotinic acid medicinal products at unknown frequency or in clinical trials with Pelzont (or the nicotinic acid component of Pelzont) in < 1% of the patients treated:
Reacţii adverse asociate acidului nicotinic Următoarele reacţii adverse asociate acidului nicotinic au fost observate în cadrul studiilor clinice sau în timpul experienţei după punerea pe piaţă cu alte medicamente care conţin acid nicotinic cu o frecvenţă necunoscută sau în cadrul studiilor clinice efectuate cu Pelzont (sau componenta de acid nicotinic din Pelzont) la < 1% dintre pacienţii trataţi:
Atrial fibrillation and other cardiac arrhythmias, palpitations, tachycardia.
Fibrilaţie atrială şi alte aritmii cardiace, palpitaţii, tahicardie.
Migraine, syncope.
Migrenă, sincopă.
Cystoid macular oedema, toxic amblyopia.
Edem macular chistoid, ambliopie toxică.
Respiratory, thoracic, and mediastinal disorders:
Tulburări respiratorii, toracice şi mediastinale:
Dyspnoea.
Dispnee.
Abdominal pain, mouth oedema, eructation, peptic ulcer.
Dureri abdominale, edem al cavităţii bucale, eructaţii, ulcer peptic.
Acanthosis nigricans, dry skin, hyperpigmentation, macular rash, sweating (night or cold sweat), vesicular rash.
Acanthosis nigricans, piele uscată, hiperpigmentare, erupţie maculară, hipersudoraţie (nocturnă sau transpiraţii reci), erupţie veziculară.
Muscular weakness, myalgia.
Slăbiciune musculară, mialgii.
Impaired glucose tolerance, gout.
Alterare a toleranţei la glucoză, gută.
Rhinitis.
Rinită.
Hypotension, orthostatic hypotension.
Hipotensiune arterială, hipotensiune ortostatică.
Asthaenia, chills, face oedema, generalised oedema, pain, peripheral oedema.
Astenie, frisoane, edem facial, edem generalizat, durere, edem periferic.
Angio-oedema, type I hypersensitivity.
Edem angioneurotic, hipersensibilitate de tip I.
Jaundice.
Icter.
Pelzont In the event of an overdose, it is reasonable to employ the usual symptomatic and supportive measures.
Pelzont În caz de supradozaj, este justificată utilizarea măsurilor uzuale simptomatice şi de susţinere a funcţiilor vitale.
Cases of overdose have been reported; the maximum dose of Pelzont taken was 5000 mg/ 100 mg.
Au fost raportate cazuri de supradozaj; doza maximă de Pelzont utilizată a fost 5000 mg/ 100 mg.
All patients recovered without sequelae.
Toţi pacienţii s- au recuperat fără sechele.
The most commonly reported adverse reactions from the subjects who received this higher dose were consistent with a high dose of nicotinic acid and included: flushing, headache, pruritus, nausea, dizziness, vomiting, diarrhoea, epigastric and abdominal pain/ discomfort, and back pain.
Reacţiile adverse cel mai frecvent raportate de către subiecţii care au primit această doză mai mare au fost cele corespunzătoare administrării unei doze mari de acid nicotinic şi au inclus: hiperemie cutanată tranzitorie, cefalee, prurit, greaţă, ameţeli, vărsături, diaree, durere/ disconfort epigastric şi abdominal şi durere lombară.
Laropiprant During controlled clinical trials in healthy subjects, single doses of up to 900 mg laropiprant and multiple doses up to 450 mg once daily for 10 days were generally well tolerated.
Laropiprant În timpul studiilor clinice controlate efectuate la subiecţi sănătoşi, doze unice de până la 900 mg laropiprant şi doze multiple de până la 450 mg o dată pe zi timp de 10 zile au fost, în general, bine tolerate.
Prolongation of collagen-induced platelet aggregation was observed in subjects taking multiple doses of 300 mg or greater (see section 5.1).
5. 1).
Pharmacotherapeutic group: nicotinic acid and derivatives, ATC code:
Grupa farmacoterapeutică: acid nicotinic şi derivaţi, codul ATC:
Nicotinic acid lowers the levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein B (apo B, the major LDL protein), triglycerides (TG), and lipoprotein(a) (Lp(a), a modified LDL particle) and elevates the levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apo A-I, the major protein component of HDL).
Acidul nicotinic determină scăderea concentraţiilor de lipoproteine cu densitate mică (LDL- C), colesterol total (CT), lipoproteine cu densitate foarte mică (VLDL- C), apolipoproteină B (apo B, principala proteină din LDL), trigliceride (TG) şi lipoproteină( a) (Lp( a), o particulă LDL modificată) şi determină creşterea concentraţiilor de lipoproteine cu densitate mare (HDL- C) şi de apolipoproteină A- I (apo A- I, principala componentă proteică din HDL).
Nicotinic acid Mechanism of action The mechanisms by which nicotinic acid modifies the plasma lipid profile are not fully understood.
Acid nicotinic Mecanism de acţiune Mecanismele prin care acidul nicotinic modifică profilul lipidic plasmatic nu sunt complet elucidate.
Nicotinic acid inhibits release of free fatty acids (FFA) from adipose tissue, which may contribute to the reduced plasma LDL-C, TC, VLDL-C, apo B, TG, and Lp(a), as well as elevated HDL-C, and apo A-I, all of which are associated with lower cardiovascular risk.
Acidul nicotinic inhibă eliberarea de acizi graşi liberi (AGL) din ţesutul adipos, ceea ce poate contribui la scăderea concentraţiilor plasmatice ale LDL- C, CT, VLDL- C, apo B, TG şi Lp( a) precum şi la creşterea concentraţiilor HDL- C şi apo A- I, toate acestea fiind asociate cu un risc cardiovascular mai scăzut.
Pharmacodynamic effects Nicotinic acid causes a relative shift in the distribution of LDL subclasses from small, dense (most atherogenic) LDL particles to larger LDL particles.
Efecte farmacodinamice Acidul nicotinic determină o modificare relativă a distribuţiei subclaselor LDL de la particule LDL mici, dense (cele mai aterogene) la particule LDL mai mari.
Nicotinic acid also elevates the HDL2 subfraction to a greater extent than the HDL3 subfraction, thereby increasing the HDL2: HDL3 ratio, which is associated with decreased cardiovascular disease risk.
De asemenea, acidul nicotinic determină creşterea subfracţiunii HDL2 într- o măsură mai mare decât a subfracţiunii HDL3, crescând astfel raportul HDL2: HDL3, care este asociat cu scăderea riscului de boală cardiovasculară.
Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis.
9 Similar LDL, lipoproteinele bogate în trigliceride şi colesterol, inclusiv VLDL, lipoproteinele cu densitate intermediară (IDL) şi restul, pot favoriza, de asemenea, apariţia aterosclerozei.